|
CCO >
Oncology >
Translational 2011 Slides
|
Wednesday, May 23, 2012 |
|
Oncology
Hot Topics in Translational Research: Transforming Cutting-Edge Discoveries to Clinical Practice
Downloadable PDFs
Identifying Tumors Expressing Predictive Markers: Lessons Learned From HER2
 |
Dennis J. Slamon, MD, PhD, reviews some of the lessons learned from targeting the HER pathway and explores how these can accelerate the development of new markers and targeted agents.
Date posted: 6/6/2011 | |
 |
Download PDF |
IGF1R: A New Target for Multiple Tumor Types
 |
Gottfried E. Konecny, MD, reviews the biological role of IGFR in cancer, potential predictive markers, the mechanism of action of agents targeting IGFR, and an overview of preclinical and clinical findings.
Date posted: 6/8/2011 | |
|
Download PDF |
Targeting the PI-3 Kinase Pathway
 |
Carlos L. Arteaga, MD, reviews the role of the PI3K pathway in the pathogenesis of cancer and explores agents targeting this pathway under investigation. Current research in predictive markers will also be briefly delineated, as well as the most recent clinical trial data and ongoing trials.
Date posted: 6/6/2011 | |
|
Download PDF |
Antireplication Agents: CDK Inhibitors and Telomerase Inhibitors
 |
Richard S. Finn, MD, discusses agents that work through an antireplication mechanism, including CDK inhibitors and telomerase inhibitors and provides an overview of preclinical and clinical findings culminating in the latest clinical data and ongoing trials in diverse tumor types.
Date posted: 6/6/2011 | |
|
Download PDF |
Angiogenesis: Using Old and New Approaches
 |
John Mackey, MD, explores novel applications and combinations of well known VEGF pathway targeting and also reviews novel agents targeting other pathways in angiogenesis and tumor vasculature.
Date posted: 6/6/2011 | |
|
Download PDF |
DNA Repair Pathways and PARP Inhibition
 |
Nicholas Turner, MD, PhD, reviews the biological role of DNA repair pathways in cancer, potential predictive markers and mutations, the use of PARP inhibitors, and an overview of preclinical and clinical findings in ovarian and breast cancers.
Date posted: 6/6/2011 | |
|
Download PDF |
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.
Contact Info
In association with
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|